CN114984298A - Cartilage tissue adhesive and preparation method and application thereof - Google Patents

Cartilage tissue adhesive and preparation method and application thereof Download PDF

Info

Publication number
CN114984298A
CN114984298A CN202210840903.5A CN202210840903A CN114984298A CN 114984298 A CN114984298 A CN 114984298A CN 202210840903 A CN202210840903 A CN 202210840903A CN 114984298 A CN114984298 A CN 114984298A
Authority
CN
China
Prior art keywords
cartilage tissue
cartilage
tissue adhesive
matrix
additive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210840903.5A
Other languages
Chinese (zh)
Inventor
潘君
王敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing University
Original Assignee
Chongqing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing University filed Critical Chongqing University
Priority to CN202210840903.5A priority Critical patent/CN114984298A/en
Publication of CN114984298A publication Critical patent/CN114984298A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/102—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Abstract

A cartilage tissue adhesive comprises two materials, namely a material 1 and a material 2, wherein the material 1 and the material 2 respectively comprise a matrix, a cross-linking agent and an additive. Mixing the matrix of material 1 or material 2 with the additive, and freezing and storing the crosslinking agent of material 1 or material 2 at-20 deg.C or below. When in use, the matrix, the additive and the cross-linking agent of the material 1 or the material 2 are taken out and uniformly mixed to obtain the material 1 or the material 2 respectively. Adding the material 1 to the surface of the cartilage tissue to be adhered, only covering the surface of the damaged cartilage tissue, and sucking away the redundant liquid components by using gauze after being properly pressed by adopting a surgical instrument; and adding the material 2 to the surface of the material 1 until the cartilage defect part is completely filled, so as to realize the functions of adhering cartilage and promoting cartilage repair and healing.

Description

Cartilage tissue adhesive and preparation method and application thereof
Technical Field
The present invention relates to materials, methods of preparation, methods of storage and use for adhering to, and repairing and regenerating damaged and torn cartilage, particularly menisci.
Technical Field
Cartilage is a translucent, elastic, predominantly supportive connective tissue. The cartilage does not contain blood vessels and lymphatic vessels, and nutrients are obtained by permeating the cartilage intercellular substance mainly through blood vessels in the cartilage membrane and subchondral bone, so that the cartilage cells are nourished. Cartilage damage is the destruction of cartilage caused by acute trauma, or chronic strain, or disease, etc. Cartilage has a low self-repairing capacity due to the lack of blood vessels within the cartilage.
The meniscus is a C-shaped cushioning structure consisting of elastic cartilage located between the femur and tibia that make up the knee joint. The edge of the joint capsule is thicker and is tightly connected with the joint capsule; the center part is thin and is in a free state. The normal meniscus has the effect of increasing tibial condyle depression and lining the medial and lateral femoral condyles to increase articular stability and cushion shock. Meniscal damage refers to the degeneration, wear or tear of the structure of the meniscus. Abnormal meniscal loosening, instability after damage to the articular ligaments, or obesity, excessive body weight, etc., are all factors that contribute to meniscal damage. Meniscal tears are breaks in the fibrocartilage of the meniscus, mainly caused by torsional forces in the knee in semi-flexion or in full flexion, and can be caused by long-term wear or acute injury. After the meniscus is torn, the original function can be partially or completely lost, interference is formed in the joint even, the normal movement of the knee joint is influenced, and secondary osteoarthritis can happen after a long time. In addition to the ability to repair itself after damage to the limbal portion, the meniscus is not self-repairing after rupture, and a fibro-cartilaginous, thin and narrow meniscus can be regenerated from the synovium after the meniscus has been removed.
Since normal activities require cartilage, including the meniscus, to perform a specific biomechanical action, which is a greater mechanical force to which cartilage, and in particular meniscus, is subjected during normal activities, there is a greater demand for adhesive material following cartilage, including meniscus, injury. The ideal cartilage adhesive material not only plays a role in filling and adhesion, but also can promote the repair and healing of cartilage per se, and realizes the repair of cartilage tissues close to autologous cartilage tissues.
Disclosure of Invention
The invention aims to provide an adhesive for adhering damaged and torn cartilage, in particular to meniscus, and a preparation method, a storage method and application thereof.
In order to achieve the above object, the present invention provides the following technical solutions:
the cartilage tissue adhesive provided by the invention consists of two materials, namely a material 1 and a material 2. Wherein both material 1 and material 2 comprise a matrix, a cross-linking agent and additives. The cross-linking agent of material 1 and material 2 may be the same, but the matrix and additives of material 1 and material 2 are different. The material 1 functions as a transition layer between the damaged cartilage and the material 2, allowing the damaged cartilage and the material 2 to be better bonded. The material 2 plays a major role in adhesion, repair and healing.
In the cartilage tissue adhesive of the present invention, the cross-linking agent of the material 1 and the material 2 is composed of one or more of the following compounds: isothiocyanates, isocyanates, acyl azides, carboimines, N-hydroxysuccinimide (NHS) esters, imides, aldehydes, epoxides, sulfonyl chlorides, carbonates, aryl halides, anhydrides, fluorophenyl esters, silicon chlorides, organometallic compounds, diphenyl phosphates, quinones, glyoxylic acid, or genipin. The organometallic compounds concerned may be sulfates or chlorides of trivalent basic iron, aluminum, cerium, tetravalent basic zirconium or titanium. The aldehyde can be formaldehyde or paraformaldehyde, glutaraldehyde, dialdehyde starch, furfural, dialdehyde cellulose. The cross-linking agent acts to form chemical cross-links between the damaged cartilage tissue and the matrix in the adhesive material 2, as well as between the damaged cartilage tissue, for adhesion purposes. The cross-linking agent of material 1 may be different from that of material 2.
The matrix of the material 1 in the cartilage tissue adhesive according to the invention may be a silicone oil or an essential oil. Its function is to dissolve and disperse the crosslinking agent and additives.
The matrix of material 2 in the cartilage tissue adhesive according to the invention may be collagen II, and/or glycosaminoglycans, and/or proteoglycans. Its function is to fill cartilage defects, support cartilage adhesion and repair.
The additive of material 1 in the cartilage tissue adhesive according to the invention may be a non-steroidal anti-inflammatory drug with an anti-inflammatory effect and/or a drug with an antibacterial effect, such as a quinolone or an antibiotic. It has antiinflammatory, antibacterial, and cartilage repairing and healing effects.
The additive of the material 2 in the cartilage tissue adhesive of the present invention may be a growth factor having a cartilage repair promoting effect, including transforming growth factor beta family (TGF- β), fibroblast growth factor (bFGF), insulin-like growth factor (IGF), Bone Morphogenetic Protein (BMP), scatter factor (HGF), platelet-derived growth factor (PDGF), or a mixture thereof, etc.; and/or cell induction factors having the effect of promoting stem cell homing, including stromal cell derived factor 1(SDF-1), macrophage Migration Inhibitory Factor (MIF), or a mixture thereof, etc.; and/or stem cells or exosomes of stem cells or extracellular vesicle extracts. Its function is to promote the repair and healing of cartilage.
The invention also provides a preparation method and a storage method of the cartilage tissue adhesive, namely, the matrix and the additive of the material 1 or the material 2 are respectively and uniformly mixed, and the cross-linking agent of the material 1 or the material 2 is independently frozen and stored at the temperature of minus 20 ℃ or below for later use.
The invention also provides a using method of the cartilage tissue adhesive, namely, the cross-linking agent of the preserved material 1 or material 2 is respectively and uniformly mixed with the mixed matrix and additive of the corresponding material 1 or material 2 to obtain the material 1 or material 2; then adding the material 1 to the surface of the cartilage tissue to be adhered, only covering the surface of the damaged cartilage tissue, and sucking away the redundant liquid components by using gauze after being properly pressed by adopting a surgical instrument; material 2 is then added to the surface of material 1 until the cartilage defect is partially filled.
The adhesive is prepared by mixing a substrate, a cross-linking agent and an additive according to a certain proportion. The ratio of the matrix, the cross-linking agent and the additive is 1 (0.001-1) to 0.0001-0.5, preferably 1:0.1: 0.001-0.01. The ratio of matrix, cross-linking agent and additives may be different for material 1 versus material 2.
In the additive for cartilage tissue adhesive material 2 of the present invention, the concentration of the growth factor for promoting cartilage repair and the cell-inducing factor for promoting stem cell homing may be 1 to 5000. mu. mol. L-1, and the amount of the stem cells may be 1X 10 3 ～10 9 。
The invention also provides the application of the cartilage tissue adhesive in the adhesion, repair and regeneration of cartilage tissues, and is particularly suitable for meniscus tissues.
Detailed Description
The invention provides a cartilage tissue adhesive with the effects of promoting repair and healing, and a preparation method, a storage method and application thereof. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to those skilled in the art are deemed to be included within the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The invention is further illustrated by the following examples:
example 1: adhesion, repair and healing of damaged menisci.
The method comprises the following steps: material 1 and material 2 were prepared and prepared. The matrix of the selected material 1 is silicone oil, the cross-linking agent is sulfosuccinimide 4- (N-maleimidomethyl) cyclohexane-1-carboxylate, and the additive is prepared by mixing the following components in a ratio of 1: 1, naproxen, an anti-inflammatory agent, and a quinolone, an antibacterial agent. Wherein the ratio of the matrix, the cross-linking agent and the additive is 1:0.1: 0.01. The matrix of material 2 was chosen in a ratio of 2: 1 collagen II and glycosaminoglycans, the cross-linking agent being in a ratio of 1: 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), and the additive is stromal cell derived factor 1 (SDF-1). Wherein the ratio of the matrix, the cross-linking agent and the additive is 1:0.05: 0.01. Respectively and uniformly mixing the matrix and the additive of the material 1 or the material 2, and freezing and storing the cross-linking agent of the material 1 or the material 2 at the temperature of-20 ℃ or below for later use.
Step two: establishing a rabbit meniscus injury animal model. After anesthesia, an arc incision with the length of 2.0 cm is made on the medial collateral ligament, the skin and subcutaneous layers are cut from the medial upper edge of the patella to the tibial tubercle, and the anterior horn, body and femoral condyle cartilage surface of the medial meniscus are exposed by a pre-curved meniscal retractor. A uniform 0.6cm long model of a 0.6cm bloodless area of longitudinal full-thickness laceration was created in the medial meniscal free margin portion with a sharp blade.
Step three: the adhesion of the meniscus is damaged. And taking out the preserved reagent, thawing, and uniformly mixing the cross-linking agent of the material 1 or the material 2 with the mixed matrix and the additive of the corresponding material 1 or the material 2 to obtain the material 1 or the material 2. Adding the material 1 to the damaged surface of the damaged meniscus, only completely covering the damaged surface, and sucking away the redundant liquid components by using gauze after being properly pressed by adopting a surgical instrument; material 2 is then added to the surface of material 1 until the meniscal cartilage lacerations are completely filled. The blank control group was not treated with any padding.
Step four: and detecting the adhesion and repair effect of the damaged meniscus. Animals were sacrificed at 2, 8, 12, 16 weeks post-surgery, gross morphology observation, histological examination, and mechanical property testing.
Example 2: adhesion, repair and healing of damaged menisci.
The method comprises the following steps: material 1 and material 2 were prepared and prepared. The matrix of the material 1 is selected to be essential oil, the cross-linking agent is dicyclohexyl diimine, and the additive is prepared by mixing the following components in a ratio of 1: 1, loxoprofen as an anti-inflammatory drug and vancomycin as an antibacterial drug. Wherein the ratio of the matrix, the cross-linking agent and the additive is 1:0.05: 0.05. The matrix of the selected material 2 is collagen II hydrogel solution, the cross-linking agent is genipin, and the additive is exosome of bone marrow mesenchymal stem cells. Wherein the ratio of the matrix, the cross-linking agent and the additive is 1:0.2: 0.1. Respectively and uniformly mixing the matrix and the additive of the material 1 or the material 2, and freezing and storing the cross-linking agent of the material 1 or the material 2 at the temperature of-20 ℃ or below for later use.
Step two: establishing a rabbit meniscus injury animal model. After anesthesia, an arc incision with the length of 2.0 cm is made on the medial collateral ligament, the skin and subcutaneous layers are cut from the medial upper edge of the patella to the tibial tubercle, and the anterior horn, body and femoral condyle cartilage surface of the medial meniscus are exposed by a pre-curved meniscal retractor. A uniform 0.6cm long model of a 0.6cm bloodless area of longitudinal full-thickness laceration was created in the medial meniscal free margin portion with a sharp blade.
Step three: the adhesion of the meniscus is damaged. And taking out the preserved reagent, thawing, and uniformly mixing the cross-linking agent of the material 1 or the material 2 with the mixed matrix and the additive of the corresponding material 1 or the material 2 to obtain the material 1 or the material 2. Adding the material 1 to the damaged surface of the damaged meniscus, only completely covering the damaged surface, and sucking away the redundant liquid components by using gauze after being properly pressed by adopting a surgical instrument; material 2 is then added to the surface of material 1 until the meniscal cartilage lacerations are completely filled. The blank control group was not treated with any padding.
Step four: and detecting the adhesion and repair effect of the damaged meniscus. Animals were sacrificed at 2, 8, 12, 16 weeks post-surgery, gross morphology observation, histological examination, and mechanical property testing.
Example 3: adhesion, repair and healing of damaged cartilage.
The method comprises the following steps: material 1 and material 2 were prepared and prepared. The matrix of the selected material 1 is essential oil, the cross-linking agent is disuccinimidyl suberate, and the additive is a mixture of 1: 1, in a ratio of 1: 1, and diacerein and the antibacterial clindamycin. Wherein the ratio of the matrix, the cross-linking agent and the additive is 1:0.08: 0.06. The substrate of the selected material 2 is a glycosaminoglycan hydrogel solution, and the cross-linking agent is a mixture of 1: 1 sodium metaperiodate (NaIO4) and sodium cyanoborohydride, and the additive was Platelet Derived Growth Factor (PDGF). Wherein the ratio of the matrix, the cross-linking agent and the additive is 1:0.1: 0.05. Respectively and uniformly mixing the matrix and the additive of the material 1 or the material 2, and freezing and storing the cross-linking agent of the material 1 or the material 2 at the temperature of-20 ℃ or below for later use.
Step two: establishing an animal model of rabbit cartilage injury. After anesthesia, an arc incision with the length of 2.0 cm is made on the medial collateral ligament in the medial approach, the skin and subcutaneous layers are cut along the upper edge of the medial side of the patella to the tibial tubercle, and a rabbit cartilage defect model with the length and width of about 0.6cm is established without damaging the cartilage surface scratch of the subchondral bone through an operation.
Step three: adhesion of defective cartilage. And taking out the preserved reagent, thawing, and uniformly mixing the cross-linking agent of the material 1 or the material 2 with the mixed matrix and the additive of the corresponding material 1 or 2 to obtain the material 1 or the material 2. Injecting the material 1 to the defect surface of the cartilage, only completely covering the damage surface, properly pressing by adopting a surgical instrument, and absorbing the redundant liquid components by using gauze; material 2 is then added to the surface of material 1 until the cartilage defect is partially filled. The blank control group was not treated with any padding.
Step four: and (5) detecting the adhesion and repair effect of the damaged cartilage. Animals were sacrificed at 2, 8, 12, 16 weeks post-surgery, gross morphology observation, histological examination, and mechanical property testing.

Claims (10)

1. A cartilage tissue adhesive is composed of two materials, namely a material 1 and a material 2. Wherein both material 1 and material 2 comprise a matrix, a cross-linking agent and an additive. The cross-linking agent of material 1 and material 2 may be the same, but the matrix and additives of material 1 and material 2 are different.
2. The cartilage tissue adhesive of claim 1 wherein the cross-linking agent of materials 1 and 2 is comprised of one or more of the following compounds: isothiocyanates, isocyanates, acyl azides, carboimines, N-hydroxysuccinimide (NHS) esters, imides, aldehydes, epoxides, sulfonyl chlorides, carbonates, aryl halides, anhydrides, fluorophenyl esters, silicon chlorides, organometallic compounds, diphenyl phosphates, quinones, glyoxylic acid, or genipin. The organometallic compounds concerned may be sulfates or chlorides of trivalent basic iron, aluminum, cerium, tetravalent basic zirconium or titanium. The aldehyde can be formaldehyde or paraformaldehyde, glutaraldehyde, dialdehyde starch, furfural, dialdehyde cellulose.
3. Cartilage tissue adhesive according to claim 1, characterised in that the matrix of the material 1 can be silicone oil or an essential oil.
4. The cartilage tissue adhesive according to claim 1 wherein the matrix of material 2 may be collagen II, and/or glycosaminoglycans, and/or proteoglycans.
5. Cartilage tissue adhesive according to claim 1, characterised in that the additive of material 1 can be a non-steroidal anti-inflammatory drug with an anti-inflammatory effect and/or a drug with an antibacterial effect.
6. The cartilage tissue adhesive according to claim 1 wherein the additive of material 2 is a growth factor having the effect of promoting cartilage repair and/or a cell induction factor having the effect of promoting stem cell homing and/or a stem cell or exosome of a stem cell or extracellular vesicle extract of a stem cell.
7. The cartilage tissue adhesive according to claims 1-6, wherein the preparation method and the storage method of the cartilage tissue adhesive are provided, wherein the matrix and the additive of the material 1 or the material 2 are respectively and uniformly mixed, and the cross-linking agent of the material 1 or the material 2 is independently stored at a temperature of-20 ℃ or below for freezing and standby.
8. The cartilage tissue adhesive according to claim 1-6, wherein the invention further provides a method for using the cartilage tissue adhesive, which comprises the steps of uniformly mixing the cross-linking agent of the preserved material 1 or material 2 with the mixed matrix and additive of the corresponding material 1 or material 2 to obtain material 1 or material 2; then adding the material 1 to the surface of the cartilage tissue to be adhered, only covering the surface of the damaged cartilage tissue, and sucking away the redundant liquid components by using gauze after being properly pressed by adopting a surgical instrument; material 2 is then added to the surface of material 1 until the cartilage defect is partially filled.
9. The cartilage tissue adhesive according to claim 1-6, wherein the ratio of the matrix, the cross-linking agent and the additive is 1 (0.001-1) to (0.0001-0.5).
10. The invention also provides the application of the cartilage tissue adhesive in the adhesion, repair and regeneration of cartilage tissues, and is particularly suitable for meniscus tissues.
CN202210840903.5A 2022-07-18 2022-07-18 Cartilage tissue adhesive and preparation method and application thereof Pending CN114984298A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210840903.5A CN114984298A (en) 2022-07-18 2022-07-18 Cartilage tissue adhesive and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210840903.5A CN114984298A (en) 2022-07-18 2022-07-18 Cartilage tissue adhesive and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN114984298A true CN114984298A (en) 2022-09-02

Family

ID=83022722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210840903.5A Pending CN114984298A (en) 2022-07-18 2022-07-18 Cartilage tissue adhesive and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114984298A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1064813A (en) * 1991-01-31 1992-09-30 罗伯特弗朗西斯肖 The method and composition of treatment and reparation cartilage defect or damage
CN1226839A (en) * 1996-06-28 1999-08-25 罗伯特·弗朗西斯·肖 Methods and compositions for treatment and repair of defects or lesions in cartilage or bone using functional barrier
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US20050043813A1 (en) * 2003-08-20 2005-02-24 Akihiko Kusanagi Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof
CN108136069A (en) * 2015-08-31 2018-06-08 科海拉医学股份有限公司 Meniscal repairs adhesive
US20210161672A1 (en) * 2018-06-11 2021-06-03 Histogenics Corporation Scaffold with adhesive for articular cartilage repair
CN113350563A (en) * 2021-03-01 2021-09-07 清华大学 Tissue adhesive and preparation method and application thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
CN1064813A (en) * 1991-01-31 1992-09-30 罗伯特弗朗西斯肖 The method and composition of treatment and reparation cartilage defect or damage
CN1226839A (en) * 1996-06-28 1999-08-25 罗伯特·弗朗西斯·肖 Methods and compositions for treatment and repair of defects or lesions in cartilage or bone using functional barrier
US20050043813A1 (en) * 2003-08-20 2005-02-24 Akihiko Kusanagi Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof
CN108136069A (en) * 2015-08-31 2018-06-08 科海拉医学股份有限公司 Meniscal repairs adhesive
US20210161672A1 (en) * 2018-06-11 2021-06-03 Histogenics Corporation Scaffold with adhesive for articular cartilage repair
CN113350563A (en) * 2021-03-01 2021-09-07 清华大学 Tissue adhesive and preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
安万新 *

Similar Documents

Publication Publication Date Title
US8642735B2 (en) Biologic replacement for fibrin clot
CA2895140C (en) Perforated osteochondral allograft compositions
CA2536094C (en) Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof
US7157428B2 (en) Method for treatment and repair of meniscal injuries
KR100531922B1 (en) a composition for cartilage therapeutics and a using method thereof
US20050043814A1 (en) Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof
US7560432B2 (en) In situ method for treatment and repair of meniscal injuries
US20040059416A1 (en) Biologic replacement for fibrin clot
AU2019222977A1 (en) Biomaterial for articular cartilage maintenance and treatment of arthritis
CN114984298A (en) Cartilage tissue adhesive and preparation method and application thereof
Sharifi et al. Articular cartilage: injury, healing, and regeneration
Steiger Gelatin-based bioadhesives for meniscal repair
WO2000078370A1 (en) Biologic replacement for fibrin clot for intra-articular use
CA2377595A1 (en) Biologic replacement for fibrin clot for intra-articular use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination